CDKN2A and breast carcinoma: High p16 expression in breast carcinoma correlates with unfavorable prognostic factors such as poor overall survival, poor disease-free survival, ER (estrogen receptor) and PR (progesterone receptor) negativity and an increased risk of relapse cancer [9].